

Table S1. Clinical characteristics of patients.

Patient	Gender/Age	Primary	Metastatic site	Prior Immunotherapy	Prior IL-2
3107	F/45	Melanoma	Lungs, LN, vertebrae, Liver*	IFN, Ontak (Denileukin diftitox)	Yes
3919	F/18	Melanoma	LN, spleen, liver*	IFN, anti-PD-1	Yes
4066	M/21	Melanoma	LN, R wrist, Lungs, L flank*	Ipilimumab, Vemurafenib and XL888 (HSP 90 inhibitor), anti-PD-1	No
4032	M/46	Colon	Lung, Liver*	None	No
4060	F/55	Colon	Pelvis*	None	No
4067	F/60	Ovarian	Cecum, LN*	Anti-PDL-1	No

* Harvest site for tumor digests and whole exomic sequencing; LN, lymph node; IFN, Interferon;